Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Journal Articles

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

Caitlin Rausch, Hagop Kantarjian, Nitin Jain, Jeffrey Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian, Yesid Alvarado Valero, Tapan Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia-Manero, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2025-1575

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5228.

https://doi.org/10.1182/blood-2025-5228

Published: 2025

Journal Articles

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Sankalp Arora, Hagop Kantarjian, Manuel Maroun, Gautam Borthakur, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Ghayas Issa, Kelly Chien, Abhishek Maiti, Maro Ohanian, Mahesh Swaminathan, Wei-Ying Jen, Farhad Ravandi, Hussein Abbas, Nicholas Short

Blood (2025) 146 (Supplement 1): 5226.

https://doi.org/10.1182/blood-2025-5226

Published: 2025

Journal Articles

Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2025-1653

Published: 2025

Journal Articles

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Roberta S. Azevedo, Christopher Manuel, Tapan Kadia, Maro Ohanian, Yesid Alvarado Valero, Wei Qiao, Jayastu Senapati, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2025-1634

Published: 2025

Journal Articles

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood (2024) 144 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2024-210779

Published: 2024

Journal Articles

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Julie Braish, Guillermo Montalban-Bravo, Farhad Ravandi, Nicholas J. Short, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Lucia Masarova, Koji Sasaki, Musa Yilmaz, Naval Daver, Gautam Borthakur, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2024-208536

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi G. Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yilmaz, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2024-211599

Published: 2024

Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Blood (2024) 144 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2024-198928

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Blood (2023) 142 (Supplement 1): 870.

https://doi.org/10.1182/blood-2023-188236

Published: 2023

Journal Articles

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood (2023) 142 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2023-190400

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only